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I would like to talk about the development of 
immunosuppression as this occurred with renal transplantation and 
then was applied to the transplantation of other organs. . This 
was an ent irely natural se quence because wi th the other organs 
(li ver, lung, heart, heart-lung, and pancreas grafts) the 
technical requirements and technical complications were so high 
that the evaluation of new immunosuppressive drugs was not really 
feasible. 
With the simple kidney transplantation model, it was 
possible to define the patterns of rejection without the 
artifacts caused by surgical complications and to assess how 
immunosuppression changed these patterns. 
CELL MEDIATED VERSUS HUMORAL REJECTION 
The collateral issues of typing which you heard about this 
morning also were analyzable only in the simple renal model. It 
became obvious in the early 1960's that cell mediated rejection 
was not the only kind of immunologic problem which we had. This 
morning, James Cerllli talked about the fact that in hyperacute 
rejection the signal event is devascularization of the kidney 
cortex despite the main renal vessels being open. It was 
recognized that hyperacute rejection was precipitated by 
antibodies such as the isoagglutinins that attach to renal cells 
if transplantation is performed across red blood cell group 
barriers (1) or more importantly if the recipient has antigraft' 
cytotoxic antibodies (2). The avoidance of hyperacute rejection 
is not dependent upon immunosuppression but rather on the 
avoidance of antibodies by tissue typing. 
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MODIFIED CELL MEDIATED REJECTION 
In 1962 and 1963 it was recognized that azathioprine and 
prednisone could be used together to modify cell mediated renal 
rejection. In Figure 1 are shown the events following 
transplantation from a brother who probably was well matched at 
the A, B, and DR loc i although we did not know th is at the 
time. The creatinine clearance which was near zero before went 
to super normal levels after operation. The rec ipient had a 
massive diuresis which was typical in those days because of the 
generally poor condi tion of the recipients ,which in turn was 
explained by the fact that chronic hemodialysis was not generally 
available. The patient had a magnificent recovery and felt 
better for about 2 weeks than he had for several years. 
The sense of well being' was temporary. Secondary 
deterioration of graft function followed with a rise in BUN, and 
a dec 1 ine in creatinine clearance. A find ing that is not much 
seen any more because of the extensive use of steroid therapy 
today was fever (Figure 1). Also, the patient gained weight and 
developed proteinurea. In our earliest kidney recipients, 
azathioprine was used alone at first (Figure 1) and steroids were 
reserved to treat proven or presumed rejection (3). 
With the institution of prednisone therapy (Figure 1), renal 
function improved and the other adverse findings including fever 
were ameliorated. As these patients were successfully treated, 
it was realized that rejection was a reversible process (1, 3). 
An additional interesting observation in some of these early 
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patients was that it became possible to greatly reduce or in a 
few instances to even stop the prednisone therapy within a 
surprisingly short time. This implied the induction of an 
altered host-graft relationship which we rashly called 
"tolerance" (3). The kidney whose function is depicted in Figure 
1 is still functioning more than 20 years later~ 
ALTERNATIVE IMMUNOSUPPRESSIVE REGIMENS 
Experiences in 1962 and 1963 such as those shown in Figure 1 
constituted the beginning of the so-called double drug therapy 
with azathioprine and prednisone that has become the standard 
throughout the world. Before this time, 6 mercaptopurine and 
azathioprine had been used as single agents, but the success rate 
was miniscule (4). 
Subsequently, a number of deviations from the original 
double drug programs have been described (Table 1), as summarized 
elsewhere (5). Perhaps the most important was the use of 
antilymphocyte globulin (ALG) as adjunctive therapy during the 
first few postoperative days or weeks (6). The addition of ALG 
to base therapy with azathioprine and prednisone has been called 
"triple drug therapy". It was of considerable interest to note a 
few years later that cyclophosphamide, the widely used anticancer 
agent, could be subst i tu ted freely for azathioprine (1) (Table 
'). Cyclophosphamide had been (and is still) thought to be a 
fairly specific drug against B lymphocytes for which reason some 
people thought it surprising that the drug was as effective as 
the azathioprine to which anti-T-lymphocyte activity had been 
attributed. 
----------------.. "-~-D--~ 
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Pr ior to 1962, the Ii tera ture about renal transplantation 
was uniformly pessimistic in all except twin cases. For this 
reason, it was remarkable how well our first wave of patients did 
unde:- treatment wi th azathioprine and prednisone. After 
consanguineous transplantation (excluding twin cases) in 1962 and 
1963. the one year graft and patient survival was almost 70J 
(1). More than half of the kidney grafts were still functioning 
at 10 years (8) and now wi th 20 years of followup the number is 
still almost half. 
It was interesting that in our subsequent experience (1964-
1966) using double drug immunosuppression for consanguineous 
transplantations was not quite as good in spite of the fact that 
an effort was made to prospectively tissue match all donors and 
recipients (8). These disappointing results were prophetic of 
those in later and much larger trials which also showed that 
tissue matching (at least at the A and B loci) was a poor 
instrument of donor and rec ipient selection except for sibling 
combinations. 
The use of the triple drug combinations provided better 
results after related transplantation and it became common year 
after year to have graft surv ivaI after related transplantation 
at or above UM~ (8). 
THE NON-RELATED DONOR 
The defect in renal transplantation and one which of course 
was transfered to all extrarenal organs was that the results were 
so poor after cadaveric transplantation or transplantation from 
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living non-related donors. In our 1962-63 series, two thirds of 
the recipients of non-related kidneys died during the first 
postoperative year of graft rejection or of complications of the 
immunosuppression used to control the rejection (1). Most of 
these donors were living related volunteers, and thus the quality 
of the grafts was generally better than could be obtained under 
the condition of cadaveric donation which pertained in those 
early years. At that time, chronic dialysis was not generally 
available, and because of this, patient and renal graft survival 
were very nearly synonymous. 
The one year survival after transplantation from nonrelated 
volunteers or cadaveric donors in our Series 2 (1964-1966) rose 
to 50%. In subsequent series from 1966 to 1972 in which the 
triple drug programs were used, including ALG, the one year 
patient survival rose to the more satisfactory levels of 80% or 
better (8). However, this increased survival was explained in 
part by .the more and more common practice of returning patients 
to dialysis in the event of an unusually hard rejection; many of 
these patients underwent retransplantation (8). 
During the decade beginning in 1970 it became a common 
practice to look at graft (not patient) survival in assessing the 
effectiveness of immunosuppression. In this same decade, there 
was a drying up of reports of cadaveric renal transplantation 
from individual centers. I suspect that the reason was that many 
surgeons who were using double drug therapy were having such poor 
graft survival that they labored under the impression that other 
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people must be doing better. Th is percept ion of th ings was 
undoubtedly aided by a tendency from a few centers to issue what 
have been termed "See what a big boy am I" reports which at times 
were based upon incomplete data or upon data pools that were 
diluted by unspec if ied numbers of related transplantations in 
addition to the cadaveric cases. 
The true state of affairs was revealed by reports from Dr. 
Paul Terasaki's center at the University of California, Los 
Angeles. Terasaki provided a mechanism for more than 100 centers 
to report their results under a cloak of anonymity. It was found 
that the one year cadaveric graft survival under conventional 
(for the most part double drug) therapy was RM~ or less (9). As 
recently as 1981, another multicenter report from the 
Southeastern Organ Procurement Foundation has shown the same 
thing (10). 
Finally, reports from centers known for the quality of 
patient-care such as the Peter Bent Brigham Hospital, showed one 
year cadaveric kidney survival of considerably less than RM~ in 
recipients who were surviving for one year at better than a 9M~ 
rate (11). Individual centers which had higher cadaveric graft 
survival almost invariably paid a price of an increased one year 
patients mortality (12). Thus differences in graft survival from 
center to center reflected in part differing philosophies about 
what kind of patient mortality to accept, and the extent to which 
immunosuppression was pushed to the limit. 
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THE WATERSHED YEAR OF 1978 
The need for fundamental changes in immunosuppression or 
some other aspect of the strategy of cadaveric transplantation 
was widely acknowledged by the time the International 
Transplantation Society met in Rome in early September, 1978. 
The possible value of matching at the DR locus was at center 
stage for the first time, and in addition Terasaki's concept of 
recipient preparation with multiple blood transfusions (1, 3) had 
been increasingly accepted. However, both of the foregoing 
approaches would have tended to restrict the numbers of patients 
treated with transplantation. 
In particular, it was obv ious that the practice of 
preoperative transfusions improved the statistics after cadaveric 
transplantation but at the cost of rendering many patients 
nontransplantable who developed widely reacting cytotoxic 
antibodies. What was happening was that part of the "transfusion 
effect" was the weeding out of strong immunologic responders. 
The transfusion approach had the capability of making the 
transplant surgeons' statistics look better, but the aims of 
society partially were being subverted by consigning a 
significant number of patients to permanent dialysis. 
In the field of immunosuppression, three major topics 
dominated the 1978 meetings. One was the use of total lymphoid 
irrad iation for preoperative rec ip ient preparation. The 
techniques had been worked out at Stanford University by Strober 
et al (14) and the first clinical trials had been begun at the 
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University of Minnesota (15). A second technique was also based 
on lymphoid depletion prior to transplantation and was a re-
examination of thoracic duct drainage (TDD) (16) which was first 
used clinically by Franksson of Stockholm more than 15 years 
earlier (17). 
The earlier trials of thoracic duct drainage had not been 
successful, partly because the pace of the immunologic changes 
caused by TDD in humans was not understood. In his original 
studies in rats, James Gowans of Oxford had shown profound 
immunodepression wi thin 5 days after beginning TDD and it was 
assumed that the same appl ied in humans. It was not until the 
late 1970's that it became clear that 20 to 30 days of effective 
thoracic duct drainage was necessary in man before an advantage 
was created for a new transplant (16). 
The necessity for such a prolonged preparation for cadaveric 
transplantation implied a high cost and excessive 
inconveni ence. In sp i te of these disadvantages, thorac ic duct 
drainage undoubtedly would have undergone a clinical renaissance 
were it not for the fact that the poss i b iii ty of better drug 
therapy also came to the fore at the same time. The incidence of 
rejection wi th appropriate TDD pretreatment was reduced to less 
than 5% in the first three months after primary cadaveric 
transplantation (16). 
The most important subject at the 1978 Rome meeting was the 
potential value of the new immunosuppressive drug cyclosporine 
which had been discovered by scientists at the Sandoz 
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Corporation, Basel, Switzerland. The immunosuppressive qualities 
of cyclosporine had been described by Borel et al (18). The drug 
was capable of inhibiting a number of experimental auto-immune 
diseases and was spectacularly effective in preventing skin graft 
rejection in rodents. The drug was described as having weak 
myelotoxic i ty, and subsequent observations have suggested that 
there may be no bone marrow tox ic i ty at all. Ca lne and his 
associates of Cambridge, England reported the first clinical 
trials with cyclosporine, and a li ttle more than a year later 
they published a classical series of observations in recipients 
of cadaveric kidneys, livers and pancreases (19). For clinical 
use, CaIne et al (19) recommended that cyclosporine be used as 
the sole immunosuppress i ve agent. In late 1979, our own tr ials 
with cyclosporine were begun, with the conclusion that the 
optimal use of cyclosporine depended upon its combination with 
steroid therapy (20). 
Our usual practice has been to begin prednisone on the day 
of operation in a dose for adults of 200 mg on the first 
postoperative day and with daily decrements of 40 mg/day until 20 
mg/day is reached as a maintenance dose in the noncomplicated 
case after 5 postoperative days. If rejection supervenes in 
spite of this therapy a second burst of steroid therapy is 
given. The dose of cyclosporine which we have used has been 
about 17.5 mg/kg/day. 
Less than half of the patients treated in this way have a 
completely untroubled convalescence. In the rest, adequate renal 
Thomas E. Starzl, MD, PhD 11 
function either is not obtained at the outset or else graft 
deterioration occurs after in1 tially satisfactory function 
(21). When a secondary decl ine in renal function occurs, it is 
necessary to devise changes in therapy that can accommodate 
either the possibilities of rejection or of cyclosporine 
nephrotoxicity. The most serious and consistent side effect of 
the agent has been renal injury, but fortunately this has almost 
always been responsive to reductions in dose. Our own hypothesis 
has been that nephrotoxicity and rejection can occur 
simultaneously (21) • 
. Our initial trials with cyclosporine were in 1919 
1980. The results were 'compared with historical controls. 
and 
In 
spite of the fact we were engaged in a learning process, the one 
year actual graft survival after primary cadaveric 
transplantation was nearly 80% (Table 2). 
At the University of Pittsburgh in 1981 a randomized trial 
was carried out in which the results under cyclosporine-steroid 
therapy were compared to those wi th conventional double drug 
treatment using azathioprine and prednisone. The divergence in 
results was so great that the trial had to be discontinued within 
less than a year. The one year primary graft surv ivaI was 90% 
under the experimental protocol compared to than less than 50% 
using conventional therapy (Table 3). The mortality during 1981 
in all groups of patients was 1%. 
An important feature of the improved immunosuppression with 
cyclosporine and steroids has been the ease with which cadaveric 
------ --------
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retransplantat ion has been possible. After retransplantation, 
our results in the pilot trials at the University of Colorado and 
subsequently at the University of Pittsburgh have resulted in 
about a 75% one year cadaver ic graft surv i val (Table 2 and 3), 
almost double that usually reported and in comparison with the 
outcome in our own institution for several preceding years. The 
fact that retransplantation can be so readily carried out wi th 
this improved immunosuppression has virtually eliminated any 
incentive to carry out persistant or excessive attempts at 
salvaging kidneys undergoing protracted or unusually severe 
rejection. 
FUTURE POLICIES IN TRANSPLANTATION 
The conclusions which have reached from observations in the 
last several years have opened up some areas for lively 
discussions. Thus what I will speculate upon might be considered 
to be controversial. My own feeling is that the use of living 
related donors will become obsolete as a result of the great 
improvements in immunosuppression and particularly those made 
possible wi th cyclosporine-steroid therapy. The role of tissue 
matching will be diminished in transplantation practices, since 
it has been so easy to override the immunologic problems caused 
by mismatches. At the same time it will be increasingly 
important to have accurate crossmatching techniques since there 
is no reason to believe that preformed antibody states can be 
successfully dealt wi th wi th cyclosporine-steroid therapy. The 
importance of sensi tization will be an important objective in 
future times and because of that the preparation of patients by 
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transfusion which I discussed earlier will become a less and less 
desirable practice. Diabetics will be easier to treat and the 
same applies to other patients currently considered to have an 
increased risk. Thus the criteria for candidacy will be 
liberalized. It seems certain that the drain of patients from 
the dialysis centers will become more rapid, but we have been 
told recently that the numbers entering dialysis will also 
increase and thus the dialysis pools will not dry up. In any 
case the interface between dialysis and transplantation will 
undoubtedly change. 
One of the previous speakers has emphasized that the 
ambience between the transplant surgeons and the nephrologists 
has sometimes been a hostile one. This will have to change. The 
nephrologists are going to have to face the fact that 
transplantation is a reliable service and probably safer than 
dialysis. Physicians who have withheld patients from cadaveric 
transplantation because of their dissatisfaction with the results 
to the present time will be in a position to change their 
minds. The question which is so paramount in importance here in 
Kuwait and which exists world wide is the extent to which the 
organ supply will be a critical limitation in renal 
transplantation. I think it is vitally important for all nations 
who wish to serve their own citizens to create a legal structure 
which will permit and even openly encourage the donation of 
organs from cadavers and under the appropriate circumstances 
(including brain death) which will permit a high expectation of 
success. 
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Figure 1. Classic rejection crisis in patient treated 20 years ago. The 
donor was a sibling. Deterioration of renal function began more 
than 2 weeks after transplantation. All stigmata of rejection 
were present except for acute hypertension and weight gain, 
which were successfully prevented by medical treatment. Acti-C-
Actinomycin C; LN - Left nephrectomy at time of transplantation; 
RN - Right nephrectomy. lmuran is synonymous with 
azathioprine. (By permission of Surg Gynec Obstet (117:385, 
1963. 
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